• Users Online: 294
  • Print this page
  • Email this page
REVIEW ARTICLE
Year : 2016  |  Volume : 3  |  Issue : 2  |  Page : 158-164

Prostate cancer and androgen deprivation therapy: Metabolic, cardiovascular and psychological side effects


1 Oncology, Urological Tumors Multidisciplinary Team, Maggiore Della Carità University Hospital, East Piedmont University, Novara, Italy
2 Urology, Urological Tumors Multidisciplinary Team, Maggiore Della Carità University Hospital, East Piedmont University, Novara, Italy
3 Radiotherapy, Urological Tumors Multidisciplinary Team, Maggiore Della Carità University Hospital, East Piedmont University, Novara, Italy
4 Pathology, Urological Tumors Multidisciplinary Team, Maggiore Della Carità University Hospital, East Piedmont University, Novara, Italy
5 Radiology, Urological Tumors Multidisciplinary Team, Maggiore Della Carità University Hospital, East Piedmont University, Novara, Italy
6 PsychoOncology, Urological Tumors Multidisciplinary Team, Maggiore Della Carità University Hospital, East Piedmont University, Novara, Italy
7 Endocrinology, Urological Tumors Multidisciplinary Team, Maggiore Della Carità University Hospital, East Piedmont University, Novara, Italy
8 Data Management, Urological Tumors Multidisciplinary Team, Maggiore Della Carità University Hospital, East Piedmont University, Novara, Italy

Correspondence Address:
Alessandra Mosca
Oncology, Urological Tumors Multidisciplinary Team, Maggiore della Carità University Hospital, East Piedmont University, Novara
Italy
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.5530/ami.2016.2.31

Rights and Permissions

Exposure to androgen deprivation therapy (ADT) by prostate cancer (PCa) patients is increasing, either in early-stage and in metastatic disease. Frequently, ADT becomes a long-term treatment, lasting even more than 10 years, starting with gonadotropin releasing hormone (GnRH) agonists or antagonists, until the newest hormonal treatments as Abiraterone and Enzalutamide. As a consequence, ADT related adverse events occurred. We reviewed the medical literature using Pubmed search terms “prostate cancer”, “androgen deprivation”, “metabolic syndrome”, “cardiovascular diseases” and “psychological assessment”. The search was limited to manuscripts published in English language between 1999 and 2016, preferring more recent review articles. Metabolic syndrome, diabetes and cardiovascular diseases, rather than PCa itself, are the most common causes of mortality, particularly in early stage PCa patients. All these adverse eff ects synergistically increase morbidity in patients taking ADT. Psychological-cognitive implications emerging during ADT result in a significant reduction of health-related quality of life of PCa patients. ADT is associated with several adverse events, which physicians andpatients should evaluate when recommending ADT. Multidisciplinary approach, with diff erent clinicians such as Urologist, Radiotherapist, Oncologist, Endocrinologist, Cardiologist, Psychologist, is mandatory for the suitable clinical management of patients with PCa submitted to ADT. Abbreviations: ADT: androgen deprivation therapy, BMI: body mass index, CV: cardiovascular, GnRH: gonadotropin releasing hormone, HDL: high-density lipoprotein, LDL: low-density lipoprotein, LHRH: luteinizing hormone releasing hormone, MS: metabolic syndrome, PCa: prostate cancer


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1535    
    Printed82    
    Emailed0    
    PDF Downloaded99    
    Comments [Add]    

Recommend this journal